RecruitingNCT06053645

The Weight of Cardiovascular Disease

The Weight of Cardiovascular Disease: A Prospective Pilot Study of Obese Adults With Cardiovascular Disease Evaluated in a Novel Cardiometabolic Clinic

Sponsor

Mayo Clinic

Enrollment

60 participants

Start Date

Apr 22, 2024

Study Type

OBSERVATIONAL

Conditions

Obesity Cardiovascular Diseases

Summary

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

BMI ≥30 kg/m2
At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease
Patients evaluated in the Cardiometabolic clinic
Willingness to complete questionnaires/surveys
Ability to complete monthly self-assessments at home

Exclusion Criteria9

BMI <30 kg/m2
Pregnancy or lactating women
Hemodynamically unstable CVD
Active malignancy
Autoimmune or systemic inflammatory diseases
Severe renal or hepatic failure
Being considered unsafe to participate as determined by the study physician
Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician
Patients with active psychosis, mania, or substance use disorders